PURPOSE: This work is intended to develop and evaluate a new polymer-lipid hybrid nanoparticle system that can efficiently load and release water-soluble anticancer drug doxorubicin hydrochloride (Dox) and enhance Dox toxicity against multidrug-resistant (MDR) cancer cells. METHODS: Cationic Dox was complexed with a new soybean-oil-based anionic polymer and dispersed together with a lipid in water to form Dox-loaded solid lipid nanoparticles (Dox-SLNs). Drug loading and release properties were measured spectrophotometrically. The in vitro cytotoxicity of Dox-SLN and the excipients in an MDR human breast cancer cell line (MDA435/LCC6/MDR1) and its wild-type line were evaluated by trypan blue exclusion and clonogenic assays. Cellular uptake and retention of Dox were determined with a microplate fluorometer. RESULTS: Dox-SLNs were prepared with a drug encapsulation efficiency of 60-80% and a particle size range of 80-350 nm. About 50% of the loaded drug was released in the first few hours and an additional 10-20% in 2 weeks. Treatment of the MDR cells with Dox-SLN resulted in over 8-fold increase in cell kill when compared to Dox solution treatment at equivalent doses. The blank SLN and the excipients exhibited little cytotoxicity. The biological activity of the released Dox remained unchanged from fresh, free Dox. Cellular Dox uptake and retention by the MDR cells were both significantly enhanced (p < 0.05) when Dox was delivered in Dox-SLN form. CONCLUSIONS: The new polymer-lipid hybrid nanoparticle system is effective for delivery of Dox and enhances its efficacy against MDR breast cancer cells.
PURPOSE: This work is intended to develop and evaluate a new polymer-lipid hybrid nanoparticle system that can efficiently load and release water-soluble anticancer drug doxorubicin hydrochloride (Dox) and enhance Doxtoxicity against multidrug-resistant (MDR) cancer cells. METHODS: Cationic Dox was complexed with a new soybean-oil-based anionic polymer and dispersed together with a lipid in water to form Dox-loaded solid lipid nanoparticles (Dox-SLNs). Drug loading and release properties were measured spectrophotometrically. The in vitro cytotoxicity of Dox-SLN and the excipients in an MDR humanbreast cancer cell line (MDA435/LCC6/MDR1) and its wild-type line were evaluated by trypan blue exclusion and clonogenic assays. Cellular uptake and retention of Dox were determined with a microplate fluorometer. RESULTS:Dox-SLNs were prepared with a drug encapsulation efficiency of 60-80% and a particle size range of 80-350 nm. About 50% of the loaded drug was released in the first few hours and an additional 10-20% in 2 weeks. Treatment of the MDR cells with Dox-SLN resulted in over 8-fold increase in cell kill when compared to Dox solution treatment at equivalent doses. The blank SLN and the excipients exhibited little cytotoxicity. The biological activity of the released Dox remained unchanged from fresh, free Dox. Cellular Dox uptake and retention by the MDR cells were both significantly enhanced (p < 0.05) when Dox was delivered in Dox-SLN form. CONCLUSIONS: The new polymer-lipid hybrid nanoparticle system is effective for delivery of Dox and enhances its efficacy against MDR breast cancer cells.
Authors: A C de Verdière; C Dubernet; F Némati; E Soma; M Appel; J Ferté; S Bernard; F Puisieux; P Couvreur Journal: Br J Cancer Date: 1997 Impact factor: 7.640
Authors: Warefta Hasan; Kevin Chu; Anuradha Gullapalli; Stuart S Dunn; Elizabeth M Enlow; J Christopher Luft; Shaomin Tian; Mary E Napier; Patrick D Pohlhaus; Jason P Rolland; Joseph M DeSimone Journal: Nano Lett Date: 2011-12-21 Impact factor: 11.189
Authors: Lily Yang; Zehong Cao; Hari Krishna Sajja; Hui Mao; Liya Wang; Huaying Geng; Hengyi Xu; Tieshan Jiang; William C Wood; Shuming Nie; Y Andrew Wang Journal: J Biomed Nanotechnol Date: 2008-12-01 Impact factor: 4.099
Authors: Samuel V Mussi; Rupa Sawant; Federico Perche; Mônica C Oliveira; Ricardo B Azevedo; Lucas A M Ferreira; Vladimir P Torchilin Journal: Pharm Res Date: 2014-02-13 Impact factor: 4.200